ReShape Lifesciences announces termination of underwriting agreement
ReShape Lifesciences announced the underwriting agreement for its underwritten public offering that priced on Aug. 7, 2018 has been terminated by the company’s underwriter for the offering in accordance with its terms due to Nasdaq’s determination that the offering was not a public offering. August 10, 2018